Once registered, you can:

  • - Read additional free articles each month
  • - Comment on articles and featured creative work
  • - Get our curated newsletters delivered to your inbox

By registering you agree to our privacy policy, terms & conditions and to receive occasional emails from Ad Age. You may unsubscribe at any time.

Are you a print subscriber? Activate your account.

Bayer, Roche in venture

Published on .

The U.S. subsidiary of Germany's Bayer AG and Roche Holding Ltd., Basel, Switzerland, will form a joint venture to market over-the-counter drugs in the U.S. Except for Bayer aspirin, the joint venture combines the companies' OTC businesses in analgesics and women's health. Roche's Aleve analgesic and Femstat 3 vaginal yeast infection treatment and Bayer's Actron and Vanquish analgesics, Midol menstrual pain reliever and Mycelex-7 vaginal yeast infection treatment will be included. The companies are still deciding which ad agencies will handle the joint efforts. Leo Burnett handles Femstat 3, DMB&B handles Aleve, Euro RSCG Tatham handles Mycelex-7 and Midol, and BBDO currently handles Actron and Vanquish.

Most Popular
In this article: